Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Bevacizumab
Lurbinectedin
Paclitaxel
Phase I study
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
13
06
2022
accepted:
03
07
2022
pubmed:
11
8
2022
medline:
16
11
2022
entrez:
10
8
2022
Statut:
ppublish
Résumé
Lurbinectedin and paclitaxel showed synergism in preclinical studies and have non-completely overlapping toxicity profiles. This phase I trial evaluated a combination of paclitaxel and lurbinectedin with/without bevacizumab in advanced tumors. This trial was divided into Group A, which evaluated weekly paclitaxel (60 or 80 mg) plus lurbinectedin (3.0-5.0 mg flat dose [FD] or 2.2 mg/m
Identifiants
pubmed: 35947247
doi: 10.1007/s10637-022-01281-z
pii: 10.1007/s10637-022-01281-z
pmc: PMC9652263
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Paclitaxel
P88XT4IS4D
PM 01183
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1263-1273Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Clin Oncol. 2010 Oct;7(10):575-82
pubmed: 20683437
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
Anticancer Res. 2006 Jan-Feb;26(1B):777-81
pubmed: 16739353
J Clin Oncol. 2009 Jul 1;27(19):3104-8
pubmed: 19451430
Ann Oncol. 2010 Sep;21(9):1804-1809
pubmed: 20150572
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Org Lett. 2000 Aug 10;2(16):2545-8
pubmed: 10956543
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Br J Pharmacol. 2010 Nov;161(5):1099-110
pubmed: 20977459
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
J Clin Oncol. 2008 Apr 1;26(10):1642-9
pubmed: 18375893
Drugs. 1994 Nov;48(5):794-847
pubmed: 7530632
Cancer Res. 2016 Nov 15;76(22):6657-6668
pubmed: 27697767
Clin Cancer Res. 2014 Apr 15;20(8):2205-14
pubmed: 24563480
Clin Cancer Res. 2010 May 1;16(9):2656-65
pubmed: 20406837
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nucleic Acids Res. 2011 Oct;39(18):8248-57
pubmed: 21727089
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
PLoS One. 2011;6(8):e22681
pubmed: 21829644
J Clin Oncol. 2015 Jul 1;33(19):2197-204
pubmed: 26014294
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Jpn J Clin Oncol. 2001 Aug;31(8):395-8
pubmed: 11574633
J Clin Oncol. 1994 Dec;12(12):2654-66
pubmed: 7989941
J Clin Oncol. 2018 Nov 1;36(31):3134-3143
pubmed: 30240327
Gynecol Oncol. 2004 Mar;92(3):813-8
pubmed: 14984946
Cancer. 1994 Mar 1;73(5):1453-5
pubmed: 8111713
Mol Cancer Ther. 2016 Oct;15(10):2399-2412
pubmed: 27630271
J Clin Oncol. 2001 Nov 15;19(22):4216-23
pubmed: 11709565
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):142-7
pubmed: 12657114
Lancet Oncol. 2020 May;21(5):645-654
pubmed: 32224306
J Clin Oncol. 2002 May 1;20(9):2365-9
pubmed: 11981009
Gynecol Oncol. 2021 Nov;163(2):237-245
pubmed: 34521554
Gynecol Oncol. 2015 Jul;138(1):18-23
pubmed: 25925990
Ann Oncol. 2017 Jun 01;28(6):1280-1287
pubmed: 28368437